Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies

Catheter Cardiovasc Interv. 2012 May 1;79(6):929-37. doi: 10.1002/ccd.23148. Epub 2011 Dec 8.

Abstract

Objective: We compared use of intravenous (IV) normal saline (NS) to sodium bicarbonate (NaHCO(3)) with or without oral N-acetylcysteine (NAC) for prevention of contrast-induced acute kidney injury (CI-AKI).

Background: CI-AKI is associated with significant adverse clinical events. Use of NAC has produced variable results. Recently, intravenous hydration with NaHCO(3) for CI-AKI prophylaxis has been adopted as standard treatment for patients with stable chronic renal disease undergoing catheterization procedures.

Methods: We prospectively enrolled 320 patients with baseline renal insufficiency scheduled to undergo catheterization. Patients were randomly assigned to receive either IV NS ± NAC (n = 161) or IV dextrose 5% in water containing 154 mEq/l of NaHCO(3) ± NAC (n = 159). IV NS was administered at 1 ml/kg body weight for 12 hr preprocedure and 12 more hr postprocedure. IV NaHCO(3) was administered at 3 ml/kg body weight for 1 hr preprocedure followed by 1 ml/kg body weight postprocedure. A 1,200 mg oral dose of NAC was given 2-12 hr preprocedure and 6-12 hr postprocedure in 50% of patients in each study arm. CI-AKI was defined as an increase of >0.5 mg/dl or >25% above baseline creatinine.

Results: Overall incidence of CI-AKI was 10.3%. There was no significant difference in incidence among the two groups (NS ± NAC 11.8% vs. NaHCO(3) ± NAC 8.8%, p = ns). Incidence of CI-AKI increased with increasing age (p = 0.001), contrast agent use >3 ml/kg body weight (p = 0.038) and diuretic use (p = 0.005).

Conclusion: Incidence of CI-AKI was no different in the NaHCO(3) group compared to NS group, and NAC did not reduce CI-AKI in the two study arms.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acetylcysteine / administration & dosage
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Cardiac Catheterization*
  • Catheterization, Peripheral*
  • Chi-Square Distribution
  • Contrast Media / adverse effects*
  • Coronary Angiography / adverse effects*
  • Creatinine / blood
  • Female
  • Fluid Therapy / methods*
  • Humans
  • Infusions, Intravenous
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced
  • Kidney Diseases / diagnosis
  • Kidney Diseases / prevention & control*
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prospective Studies
  • Renal Insufficiency / blood
  • Renal Insufficiency / complications*
  • Renal Insufficiency / diagnosis
  • Risk Assessment
  • Risk Factors
  • Sodium Bicarbonate / administration & dosage*
  • Sodium Chloride / administration & dosage*
  • Time Factors
  • Treatment Outcome
  • Vascular Diseases / complications
  • Vascular Diseases / diagnostic imaging
  • Vascular Diseases / therapy*
  • Wisconsin

Substances

  • Biomarkers
  • Contrast Media
  • Sodium Chloride
  • Sodium Bicarbonate
  • Creatinine
  • Acetylcysteine